Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients

From: Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma

Characteristic

Number

Number of patients

N = 27

%

Age at enrolment (years)

  

 Median

59

 Range

23-80

Gender

  

 Male

15

56%

 Female

12

44%

Stage of disease at baseline

  

 Stage IV

  

 M1a

4

15%

 M1b

4

15%

 M1c

19

70%

Period of time with metastases

  

 Median

2.5 months

 Range

0-115 months

LDH

  

 Normal (≤333)

14

54%

 High (>333)

4

15%

 Unknown

9

35%

BRAF mutation

  

 WT

9

35%

 V600E

11

42%

 V600K

5

19%

 K601E

1

4%

 unknown

1

4%

Treatment (post enrolment)

  

 Vemurafenib

12

46%

 Ipilimumab

4

15%

 Dacarbazine

5

19%

 Surgery

4

15%

 Dabrafenib/Trametinib

1

4%

 No treatment

1

4%